Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AQST NASDAQ:ENGN NASDAQ:NVCT NASDAQ:VALN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAQSTAquestive Therapeutics$4.05+2.7%$4.21$2.93▼$7.55$507.53M1.453.05 million shs821,134 shsENGNenGene$1.90+1.3%$1.74$1.40▼$12.25$126.95M-0.281.08 million shs81,770 shsNVCTNuvectis Pharma$19.42+7.7%$14.75$5.55▼$29.27$515.48M-0.24157,102 shs82,861 shsVALNValneva$4.91+1.3%$5.49$4.84▼$12.25$465.44M1.7753,837 shs1,652 shs7 Stocks That Could Lead the Next Market BoomTesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAQSTAquestive Therapeutics-4.37%-2.96%-16.08%-9.22%-6.19%ENGNenGene+2.75%+0.54%+8.72%-78.03%-50.66%NVCTNuvectis Pharma-5.80%-2.22%+30.46%+110.14%+131.15%VALNValneva-3.20%-7.98%-10.04%-18.38%-24.73%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAQSTAquestive Therapeutics$4.05+2.7%$4.21$2.93▼$7.55$507.53M1.453.05 million shs821,134 shsENGNenGene$1.90+1.3%$1.74$1.40▼$12.25$126.95M-0.281.08 million shs81,770 shsNVCTNuvectis Pharma$19.42+7.7%$14.75$5.55▼$29.27$515.48M-0.24157,102 shs82,861 shsVALNValneva$4.91+1.3%$5.49$4.84▼$12.25$465.44M1.7753,837 shs1,652 shs7 Stocks That Could Lead the Next Market BoomTesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAQSTAquestive Therapeutics-4.37%-2.96%-16.08%-9.22%-6.19%ENGNenGene+2.75%+0.54%+8.72%-78.03%-50.66%NVCTNuvectis Pharma-5.80%-2.22%+30.46%+110.14%+131.15%VALNValneva-3.20%-7.98%-10.04%-18.38%-24.73%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAQSTAquestive Therapeutics 3.00Buy$8.50110.14% UpsideENGNenGene 2.14Hold$11.05482.87% UpsideNVCTNuvectis Pharma 2.33Hold$35.0080.22% UpsideVALNValneva 2.20Hold$11.98144.14% UpsideCurrent Analyst Ratings BreakdownLatest ENGN, AQST, NVCT, and VALN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/17/2026AQSTAquestive Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)7/6/2026NVCTNuvectis Pharma UBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$33.007/6/2026NVCTNuvectis Pharma Roth CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$20.00 ➝ $33.006/22/2026NVCTNuvectis Pharma HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$13.00 ➝ $39.006/18/2026VALNValneva Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)6/18/2026ENGNenGene Morgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeEqual Weight ➝ Underweight$3.006/16/2026ENGNenGene HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$6.00 ➝ $4.006/12/2026NVCTNuvectis Pharma HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$10.00 ➝ $13.006/5/2026NVCTNuvectis Pharma Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)5/15/2026ENGNenGene Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)5/14/2026ENGNenGene UBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetNeutral$9.00 ➝ $2.00(Data available from 7/21/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAQSTAquestive Therapeutics$44.54M11.39N/AN/A($0.28) per share-14.45ENGNenGeneN/AN/AN/AN/A$2.60 per shareN/ANVCTNuvectis PharmaN/AN/AN/AN/A$0.72 per shareN/AVALNValneva$197.56M2.36N/AN/A$1.39 per share3.53Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAQSTAquestive Therapeutics-$83.78M-$0.61N/AN/AN/A-137.08%N/A-49.33%8/10/2026 (Estimated)ENGNenGene-$117.30M-$2.17N/AN/AN/AN/A-56.06%-45.64%9/14/2026 (Estimated)NVCTNuvectis Pharma-$26.44M-$1.31N/AN/AN/AN/A-161.00%-98.88%8/4/2026 (Estimated)VALNValneva-$130.33M-$1.87N/A2.60N/A-88.87%-107.63%-33.02%8/11/2026 (Estimated)Latest ENGN, AQST, NVCT, and VALN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/11/2026Q2 2026VALNValneva-$0.1898N/AN/AN/A$44.15 millionN/A8/10/2026Q2 2026AQSTAquestive Therapeutics-$0.10N/AN/AN/A$11.42 millionN/A8/4/2026Q2 2026NVCTNuvectis Pharma-$0.25N/AN/AN/AN/AN/A6/15/2026Q2 2026ENGNenGene-$0.48-$0.43+$0.05-$0.43N/AN/A5/13/2026Q1 2026AQSTAquestive Therapeutics-$0.14-$0.07+$0.07-$0.07$10.90 million$14.45 million5/13/2026Q1 2026VALNValneva-$0.1485-$0.42-$0.2715-$0.42$54.69 million$36.16 million5/5/2026Q1 2026NVCTNuvectis Pharma-$0.30-$0.26+$0.04-$0.26N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthAQSTAquestive TherapeuticsN/AN/AN/AN/AN/AENGNenGeneN/AN/AN/AN/AN/ANVCTNuvectis PharmaN/AN/AN/AN/AN/AVALNValnevaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAQSTAquestive TherapeuticsN/A4.103.85ENGNenGene0.1012.5712.57NVCTNuvectis PharmaN/A2.272.27VALNValneva2.142.141.60Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAQSTAquestive Therapeutics32.45%ENGNenGene64.16%NVCTNuvectis Pharma96.77%VALNValneva11.39%Insider OwnershipCompanyInsider OwnershipAQSTAquestive Therapeutics6.81%ENGNenGene10.50%NVCTNuvectis Pharma28.55%VALNValneva14.91%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAQSTAquestive Therapeutics160125.47 million116.92 millionOptionableENGNenGene3166.99 million59.95 millionN/ANVCTNuvectis Pharma826.53 million18.95 millionNot OptionableVALNValneva70094.89 million80.74 millionNot OptionableENGN, AQST, NVCT, and VALN HeadlinesRecent News About These CompaniesValneva (NASDAQ:VALN) and IM Cannabis (NASDAQ:IMCC) Critical ContrastJuly 20 at 2:58 AM | americanbankingnews.comValneva (NASDAQ:VALN) Shares Gap Up - What's Next?July 13, 2026 | marketbeat.comValneva SE Sponsored ADRJuly 11, 2026 | cnn.comValneva SE Sponsored ADR (NASDAQ:VALN) Receives $11.97 Consensus Target Price from BrokeragesJuly 11, 2026 | americanbankingnews.comValneva (NASDAQ:VALN) vs. High Tide (NASDAQ:HITI) Head to Head ContrastJuly 10, 2026 | americanbankingnews.comExperimental vaccine shows promise against dangerous intestinal illnessJuly 7, 2026 | msn.comIf a Lyme disease vaccine gets approved, how would it go over? We asked huntersJune 28, 2026 | msn.comNew research may lead to a vaccine against severe diarrheaJune 26, 2026 | medicalxpress.comMValneva SE (VALN) Shareholder/Analyst Call - SlideshowJune 25, 2026 | seekingalpha.comResearch may help pave the way for new vaccine targeting diarrheal diseaseJune 25, 2026 | news-medical.netNValneva SE (VALN) Shareholder/Analyst Call Prepared Remarks TranscriptJune 25, 2026 | seekingalpha.comValneva Announces Successful Outcome of its Annual General MeetingJune 25, 2026 | globenewswire.comValneva Announces Availability of Documentation for its Annual General MeetingJune 4, 2026 | globenewswire.comVALNEVA:Declaration of shares and voting rights - Status as of May 31, 2026June 3, 2026 | finance.yahoo.comValneva annonce sa participation à des conférences investisseurs aux États-Unis et en EuropeMay 28, 2026 | globenewswire.comValneva to Participate at U.S. and European Investor Conferences in JuneMay 28, 2026 | globenewswire.comValneva SE 2026 Q1 - Results - Earnings Call PresentationMay 16, 2026 | seekingalpha.comValneva SE (VALN) Q1 2026 Earnings Call TranscriptMay 13, 2026 | seekingalpha.comValneva SE (INRLF) Q1 2026 Earnings Call Highlights: Promising Vaccine Developments Amid ...May 13, 2026 | uk.finance.yahoo.comValneva to lay off up to 15% of workforce in face of ‘adverse trend’ in travel vaccinesMay 13, 2026 | fiercebiotech.comFValneva Reports First Quarter 2026 Financial Results and Provides Corporate UpdatesMay 13, 2026 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeENGN, AQST, NVCT, and VALN Company DescriptionsAquestive Therapeutics NASDAQ:AQST$4.04 +0.11 (+2.66%) As of 01:18 PM Eastern This is a fair market value price provided by Massive. Learn more.Aquestive Therapeutics, Inc. operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder. Its proprietary product candidates comprise Libervant, a buccal soluble film formulation of diazepam for the treatment of seizures; KYNMOBI, a sublingual film formulation of apomorphine for the treatment of episodic off-periods in Parkinson's disease; and Exservan, an oral soluble film formulation of riluzole for the treatment of amyotrophic lateral sclerosis. The company's proprietary pipeline of complex molecule product includes AQST-108, a sublingual film formulation delivering systemic epinephrine for the treatment of conditions other than anaphylaxis; and Anaphylm, an epinephrine sublingual film for the emergency treatment of allergic reactions, including anaphylaxis. In addition, it develops Adrenaverse, an epinephrine prodrug platform. The company was incorporated in 2004 and is headquartered in Warren, New Jersey.enGene NASDAQ:ENGN$1.90 +0.03 (+1.34%) As of 01:19 PM Eastern This is a fair market value price provided by Massive. Learn more.enGene Holdings Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin. The company was founded in 2023 and is based in Saint-Laurent, Canada.Nuvectis Pharma NASDAQ:NVCT$19.42 +1.39 (+7.71%) As of 01:18 PM Eastern This is a fair market value price provided by Massive. Learn more.Nuvectis Pharma, Inc., a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. The company's lead product candidate is NXP800, a novel small molecule that is in Phase 1b clinical trials for the treatment of patients with platinum-resistant, ARID1a-mutated ovarian carcinoma. It is also developing NXP900, a small molecule drug candidate, which is in Phase 1a clinical trails that inhibits the Proto-oncogene c-Src and YES1 kinases. It has license agreement with the CRT Pioneer Fund for the NXP800 and any of related derivatives; and the University of Edinburgh for the NXP900 and any of associated derivatives. The company was formerly known as Centry Pharma, Inc. and changed its name to Nuvectis Pharma, Inc. in July 2021. Nuvectis Pharma, Inc. was incorporated in 2020 and is based in Fort Lee, New Jersey.Valneva NASDAQ:VALN$4.90 +0.07 (+1.34%) As of 01:13 PM Eastern This is a fair market value price provided by Massive. Learn more.Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine. The company also develops VLA15, a vaccine candidate, which is in Phase III clinical trial against Borrelia, the bacterium that causes Lyme disease; VLA1553, a vaccine candidate, which is in Phase III clinical trial against the chikungunya virus; VLA1554, a vaccine candidate targeting human metapneumovirus; and VLA2112, a vaccine candidate to treat patients with epstein-barr virus. It sells its products in the United States, Canada, Germany, Austria, Nordics, the United Kingdom, France, rest of European countries, and internationally. Valneva SE has collaborations with Pfizer, Inc. to co-develop and commercialize its Lyme disease vaccine; and Instituto Butantan for the development, manufacturing, and marketing of single-shot chikungunya vaccine. The company was founded in 1998 and is based in Saint-Herblain, France. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Alphabet Is Planning a New AI Chip. Here's Why It Matters Ahead of Earnings Industrial and Utility Giants Boost Dividends as Data Center Tailwinds Build IREN’s $2.8 Billion AI Contract Haul Changes the Stock’s Story 2 ETFs to Access the World's Best-Performing Stock Markets In 2026 Microsoft's AI Bet Could Rewrite AMD's Growth Story Buy, Hold, or Wait: 3 Small-Cap Stocks Telling Different Stories The Ugliest Stocks in the Market Just Got a Very Expensive Vote of Confidence Is Domino's Stock Serving Up a Buying Opportunity? Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
